SCHEMBL8916747

SCHEMBL8916747

O=c1ccc2cc(Cc3ccccc3-n3ccnc3)ccc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 2/20 0.45
PDE3B Q13370 2/20 0.45
PDE3A Q14432 2/20 0.45
CHEK1 O14757 1/20 0.38
IDO1 P14902 1/20 0.37
IDH1 O75874 1/20 0.37
CYP19A1 P11511 2/20 0.36
PKM P14618 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
HTR5A P47898 1/20 0.36
FGFR1 P11362 1/20 0.36
IL4I1 Q96RQ9 1/20 0.35
CA12 O43570 2/20 0.35
CA9 Q16790 2/20 0.35
CA1 P00915 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10582405 0.83 GAA (0.40) PDE3BPDE3AIDO1PKMHTR5A
SCHEMBL9190610 0.79 HTR5A (0.38) CHEK1IDO1IDH1CYP19A1CYP11B1
SCHEMBL7453705 0.78 HTR5A (0.40) IDO1CYP19A1CYP11B1CYP11B2HTR5A
SCHEMBL9663508 0.78 IDO1 (0.37) TBXAS1PDE3BPDE3AIDO1CYP19A1
SCHEMBL669278 0.77 KDM4E (0.46) IDH1ALDH1A1
SCHEMBL9760033 0.77 SIRT6 (0.39) CHEK1IDO1CYP19A1CYP11B1HTR5A
SCHEMBL9760013 0.77 ADORA3 (0.42) CA12CA9
SCHEMBL4553696 0.76 TBXAS1 (0.40) TBXAS1PDE3BPDE3ACYP19A1CYP11B1
SCHEMBL9663761 0.75 CYP11B1 (0.43) TBXAS1PDE3BPDE3AIDO1CYP19A1
SCHEMBL9078567 0.75 FGFR1 (0.41) IDO1CYP19A1CYP11B1CYP11B2HTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5612354-A CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-18 US disclosed
US-5441954-A Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells JANSSEN PHARMACEUTICA N. V. (BE) 1995-08-15 US disclosed
EP-0371564-B1 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-07-12 EP disclosed
US-5268380-A Therapy for keratinization in mammals JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-07 US disclosed
US-5185346-A Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents HANSSEN PHARMACEUTICA (BE) 1993-02-09 US disclosed